Literature DB >> 26139080

The role of GRIK4 gene in treatment-resistant depression.

Elena Milanesi1, Cristian Bonvicini2, Chiara Congiu3, Marco Bortolomasi4, Giulio Gainelli4, Massimo Gennarelli2, Alessandra Minelli3.   

Abstract

Several lines of evidence implicate abnormalities in glutamatergic neural transmission in major depressive disorder (MDD) and treatment response. A high percentage of MDD patients do not respond adequately to antidepressants and are classified as having treatment-resistant depression (TRD). In this study we investigated five GRIK4 variants, previously associated with antidepressants response, in an Italian cohort of 247 MDD no-TRD and 380 TRD patients. We found an association between rs11218030 G allele and TRD. Moreover, significant associations between rs11218030 and rs1954787 and the presence of psychotic symptoms were observed. In conclusion, our data support the involvement of GRIK4 in TRD and in the risk of developing psychotic symptoms during depressive episodes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26139080      PMCID: PMC6863631          DOI: 10.1017/S0016672315000142

Source DB:  PubMed          Journal:  Genet Res (Camb)        ISSN: 0016-6723            Impact factor:   1.588


  20 in total

Review 1.  The hidden third: improving outcome in treatment-resistant depression.

Authors:  Thomas E Schlaepfer; Hans Agren; Palmiero Monteleone; Cristobal Gasto; William Pitchot; Frederick Rouillon; David J Nutt; Siegfried Kasper
Journal:  J Psychopharmacol       Date:  2012-01-11       Impact factor: 4.153

2.  Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression.

Authors:  Alessandro Serretti; Alberto Chiesa; Concetta Crisafulli; Isabelle Massat; Sylvie Linotte; Raffaella Calati; Siegfried Kasper; Ursula Bailer; Yves Lecrubier; Martin Fink; Irina Antonijevic; Carlos Forray; Lenore Snyder; Joseph Bollen; Joseph Zohar; Diana De Ronchi; Daniel Souery; Julien Mendlewicz
Journal:  Neuropsychobiology       Date:  2012-01-05       Impact factor: 2.328

3.  Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study.

Authors:  P A Boyer; P Skolnick; L H Fossom
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444

Review 4.  When at first you don't succeed: sequential strategies for antidepressant nonresponders.

Authors:  M E Thase; A J Rush
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

5.  Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment.

Authors:  G Nowak; Y Li; I A Paul
Journal:  Eur J Pharmacol       Date:  1996-01-04       Impact factor: 4.432

Review 6.  Major depression.

Authors:  Susan M Bentley; Genevieve L Pagalilauan; Scott A Simpson
Journal:  Med Clin North Am       Date:  2014-09       Impact factor: 5.456

7.  AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.

Authors:  Antonio Drago; Ina Giegling; Martin Schäfer; Annette M Hartmann; Marion Friedl; Bettina Konte; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Alessandro Serretti; Dan Rujescu
Journal:  Eur Neuropsychopharmacol       Date:  2012-09-11       Impact factor: 4.600

8.  Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.

Authors:  Mengjia Pu; Zhijun Zhang; Zhi Xu; Yanyan Shi; Leiyu Geng; Yonggui Yuan; Xiangrong Zhang; Gavin P Reynolds
Journal:  Pharmacogenomics       Date:  2013-02       Impact factor: 2.533

9.  GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis.

Authors:  Daniel M Kawaguchi; Stephen J Glatt
Journal:  Pharmacogenomics       Date:  2014-08       Impact factor: 2.533

10.  Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISC1, GRIK4 and NRG1.

Authors:  Douglas H R Blackwood; Ben J Pickard; Pippa A Thomson; Kathryn L Evans; David J Porteous; Walter J Muir
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

View more
  6 in total

Review 1.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 2.  Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.

Authors:  Rafael T de Sousa; Alexandre A Loch; André F Carvalho; André R Brunoni; Marie Reine Haddad; Ioline D Henter; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Neuropsychopharmacology       Date:  2016-08-11       Impact factor: 7.853

Review 3.  Exciting Times: New Advances Towards Understanding the Regulation and Roles of Kainate Receptors.

Authors:  Ashley J Evans; Sonam Gurung; Jeremy M Henley; Yasuko Nakamura; Kevin A Wilkinson
Journal:  Neurochem Res       Date:  2017-12-21       Impact factor: 3.996

4.  Prioritization and comprehensive analysis of genes related to major depressive disorder.

Authors:  Yi Liu; Pengfei Fan; Shiyuan Zhang; Yidan Wang; Dan Liu
Journal:  Mol Genet Genomic Med       Date:  2019-04-09       Impact factor: 2.183

5.  GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.

Authors:  Qianqian Sun; Fan Yuan; Ruixue Yuan; Decheng Ren; Yuhao Zhu; Yan Bi; Jiaxin Hu; Zhenming Guo; Fei Xu; Weibo Niu; Gaini Ma; Xi Wu; Fengping Yang; Lu Wang; Xingwang Li; Tao Yu; Lin He; Guang He
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 6.  The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives.

Authors:  Chiara Fabbri; Filippo Corponi; Daniel Souery; Siegfried Kasper; Stuart Montgomery; Joseph Zohar; Dan Rujescu; Julien Mendlewicz; Alessandro Serretti
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.